A Phase 3 interventional study of Venetoclax and Azacitidine in Acute Myeloid Leukemia (AML) and Cancer, sponsored by AbbVie. Terminated at 165 sites in 18 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 202 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 144 under way, 21 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.
Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 9th largest by enrollment, is one of 16 that started in 2020, is one of 16 in phase 3, and was the 41st registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →116 of the 202 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18–59
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 60+
Virginia Commonwealth University · Sites in United States
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
202 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 127 · Phase 3 26 · Phase 4 5
First in 2010; this study’s year is marked. 16 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 465 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 57 across the 202 interventional studies. Of the 46 that completed or were terminated, 15 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 202 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
43 studies in Leukemia, Myeloid, Acute by AbbVie: 4 open now, 10 under way, 3 of them phase 3. Of 31 finished, 7 (23%) have results posted.
Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, this one is the 2nd largest by enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2020, is one of 7 in phase 3, and was the 25th registered.
AbbVie’s Leukemia, Myeloid, Acute studies by the year they started, since 2010.
38 of the studies testing venetoclax in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07264010Phase 3Nanfang Hospital, Southern Medical UniversitySorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study | 2026-12-30 |
| NCT07486479Phase 3The First Affiliated Hospital of Soochow UniversityVenetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | 2026-12-31 |
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT07514936Phase 3Chinese PLA General HospitalVenetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | 2027-09-30 |
Add all 38 to your calendar (.ics) → With an account.
Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, from their registry updates:
Among AbbVie’s 43 in Leukemia, Myeloid, Acute:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when given as maintenance therapy following allogeneic stem cell transplantation (SCT).
This study will have 2 parts: Part 1 (Dose Confirmation), which may include participants who are greater than or equal to 18 years old; Part 2 (Randomization) which may include participants who are greater than or equal to 12 years old. During Part 1, recommended Phase 3 dose of venetoclax in combination with azacitidine will be determined and during Part 2, the efficacy and safety of venetoclax with azacitidine (Part 2 Arm A) will be compared with BSC (Part 2 Arm B).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered various doses and dose regiments of venetoclax and AZA. Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days)
Drug: Venetoclax · Drug: Azacitidine · Other: Best Supportive Care (BSC)
Participants will receive treatment as prescribed by their physician according to the BSC for up to 24 cycles (1 cycle = 28 days)
Other: Best Supportive Care (BSC)
Participants will be administered with venetoclax and AZA at a dose level determined in Part 1 in addition to best supportive care (when required). Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days).
Drug: Venetoclax · Drug: Azacitidine · Other: Best Supportive Care (BSC)
Tablet; Oral
Also known as: ABT-199, GDC-0199, VENCLEXTA
Subcutaneous (SC) or intravenous (IV) injection
BSC is the best supportive care, without AML directed therapy, determined per the investigator and institutional guidelines.
Number of Participants With Dose-Limiting Toxicities (DLTs) Following Administration of Venetoclax and Azacitidine (Part 1)
DLTs were any of the hematologic, nonhematologic toxicities, adverse events (AEs) occurring following administration of venetoclax and AZA as described in the protocol and evaluated by the Investigator and the sponsor.
Time frame: Up to 28 days
Overall Survival (OS) (Part 2)
OS was defined as the time from the date of randomization to the date of death from any cause.
Time frame: Up to approximately 41 months
Morphologic Relapse-Free Survival (RFS) (Part 2)
Morphologic relapse from AML was defined as bone marrow blasts of \>= 5% or reappearance of blasts in the peripheral blood not attributable to any other cause (e.g., bone marrow regeneration) in at least 2 peripheral blood samples at least one week apart or development of extramedullary disease after achieving a complete remission (CR) or complete remission with incomplete count recovery (CRi); or the date of death from any cause, whichever comes first as determined by the investigator.
Time frame: Up to approximately 41 months
Composite Relapse-Free Survival (RFS) (Part 2)
Composite RFS was defined as the time from randomization from either morphologic relapse from AML, or non-morphologic relapse from AML, whichever comes first. Non-morphologic relapse from AML was defined as increase in disease burden determined by standard methods with reappearance or acquisition of new findings with or without change in anti-leukemic treatment per investigator decision due to cytogenetic abnormalities or change in molecular marker or measurable residual disease by multiparameter flow with sensitivity to at least 10\^-3; or the date of death from any cause, whichever came first as determined by the investigator.
Time frame: Up to approximately 41 months
Graft-versus-Host Disease (GvHD)-Free, Relapse Free Survival (GRFS) (Part 2)
GRFS was defined as the time from the date of randomization to occurrence of disease relapse or incidence of GvHD or death from any cause.
Time frame: Up to approximately 41 months
Rate of Participants Without Higher Grade of GvHD (Part 2)
Rate of Participants without higher grade of GvHD was defined as the percentage of participants without grade 2 or higher for acute graft-versus-host disease (aGvHD) and moderate/severe for chronic graft-versus-host disease (cGvHD) assessed by investigator at 90 days after randomization.
Time frame: 90 days after randomization
Change From Baseline in Physical Functioning Subscore as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) (Part 2)
The EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales. The physical functioning score, reported here, ranged from 0 to 100, with a higher score indicating a better level of functioning. Positive changes from baseline indicate improvement.
Time frame: Baseline, Month 6
Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Cancer Fatigue Short Form (SF) 7a Score (Part 2)
PROMIS Cancer Fatigue SF is a seven item questionnaire that assesses the impact and experience of fatigue over the past 7 days. All questions employ the following five response options: 1 = Not at all, 2 = A little bit, 3 = Somewhat, 4 = Quite a bit, and 5 = Very much. The total raw score is the sum of the responses to each question and is converted to a T-score. The T-score re-scales the total raw score to a standardized score with a mean of 50 and a standard deviation of 10. T-Scores range from 29.4 to 83.2, with higher scores indicating more fatigue. Negative changes from baseline indicate improvement.
Time frame: Baseline, Month 6
Percentage of Participants With Measurable Residual Disease (MRD) Conversion in Participants With MRD >= 10^-3 at Baseline (Part 2)
MRD conversion rate was defined as the percentage of participants who convert to MRD \< 10\^-3 after initiation of treatment. The population for MRD analysis included participants whose bone marrow was MRD positive (\>=10\^-3, as determined by central flow cytometry) at baseline prior to randomization.
Time frame: Up to approximately 41 months
Time to Deterioration in Global Health Status (GHS)/Quality of Life (QoL) in Adult Participants (Part 2)
Time to deterioration was defined as number of days from randomization to either deterioration of \>= 5 points based on the EORTC QLQ-C30 version 3 or death due to any cause. The GHS/QoL scale includes 2 questions in which participants were asked to rate their overall health and overall quality of life during the past week on a scale from 1 (very poor) to 7 (excellent). The 2 scores were averaged and transformed to a scale from 0 to 100, where a high score represents a high QoL.
Time frame: Up to approximately 41 months
Change From Baseline in European Quality-of-Life-5 Dimensional-5-Level (EQ-5D-5L) Score
The EQ-5D-5L is a generic preference instrument that has been validated in numerous populations and has 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, each of which are rated on five levels of severity (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, 5: extreme problems) with higher scores representing higher symptom burden. A negative change from baseline indicates improvement in health status.
Time frame: Baseline, Month 6
| Milestone | Part 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD | Part 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QD | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD |
|---|---|---|---|---|
| Started | 30 | 5 | 0 | 0 |
| Received at least 1 dose of study drug | 30 | 5 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 30 | 5 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Withdrew: Death | 11 | 3 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 18 | 2 | 0 | 0 |
| Milestone | Part 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD | Part 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QD | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD |
|---|---|---|---|---|
| Started | 0 | 0 | 216 | 214 |
| Randomized to itt population | 0 | 0 | 216 | 214 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 216 | 214 |
| Withdrew: Withdrawal by subject | 0 | 0 | 25 | 12 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 46 | 55 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 142 | 144 |
| Withdrew: Other than specified | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 2 |
DLTs were any of the hematologic, nonhematologic toxicities, adverse events (AEs) occurring following administration of venetoclax and AZA as described in the protocol and evaluated by the Investigator and the sponsor.
| Participants | Part 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD | Part 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QD |
|---|---|---|
| Number of Participants With Dose-Limiting Toxicities (DLTs) Following Administration of Venetoclax and Azacitidine (Part 1) | 3 | 0 |
OS was defined as the time from the date of randomization to the date of death from any cause.
| months | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD |
|---|---|---|
| Overall Survival (OS) (Part 2) | NA (NA to NA) | NA (NA to NA) |
Morphologic relapse from AML was defined as bone marrow blasts of \>= 5% or reappearance of blasts in the peripheral blood not attributable to any other cause (e.g., bone marrow regeneration) in at least 2 peripheral blood samples at least one week apart or development of extramedullary disease after achieving a complete remission (CR) or complete remission with incomplete count recovery (CRi); or the date of death from any cause, whichever comes first as determined by the investigator.
| months | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD |
|---|---|---|
| Morphologic Relapse-Free Survival (RFS) (Part 2) | NA (34.45 to NA) | NA (NA to NA) |
Composite RFS was defined as the time from randomization from either morphologic relapse from AML, or non-morphologic relapse from AML, whichever comes first. Non-morphologic relapse from AML was defined as increase in disease burden determined by standard methods with reappearance or acquisition of new findings with or without change in anti-leukemic treatment per investigator decision due to cytogenetic abnormalities or change in molecular marker or measurable residual disease by multiparameter flow with sensitivity to at least 10\^-3; or the date of death from any cause, whichever came first as determined by the investigator.
| months | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD |
|---|---|---|
| Composite Relapse-Free Survival (RFS) (Part 2) | NA (35.45 to NA) | NA (NA to NA) |
GRFS was defined as the time from the date of randomization to occurrence of disease relapse or incidence of GvHD or death from any cause.
| months | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD |
|---|---|---|
| Graft-versus-Host Disease (GvHD)-Free, Relapse Free Survival (GRFS) (Part 2) | 11.1 (6.57 to 19.22) | 12.2 (8.31 to 24.94) |
Rate of Participants without higher grade of GvHD was defined as the percentage of participants without grade 2 or higher for acute graft-versus-host disease (aGvHD) and moderate/severe for chronic graft-versus-host disease (cGvHD) assessed by investigator at 90 days after randomization.
| percentage of participants | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD |
|---|---|---|
| Rate of Participants Without Higher Grade of GvHD (Part 2) | 63.4 (56.62 to 69.86) | 58.9 (51.97 to 65.54) |
The EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales. The physical functioning score, reported here, ranged from 0 to 100, with a higher score indicating a better level of functioning. Positive changes from baseline indicate improvement.
| score on a scale | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD |
|---|---|---|
| Change From Baseline in Physical Functioning Subscore as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) (Part 2) | 5.29 ± 1.29 | 4.98 ± 1.23 |
PROMIS Cancer Fatigue SF is a seven item questionnaire that assesses the impact and experience of fatigue over the past 7 days. All questions employ the following five response options: 1 = Not at all, 2 = A little bit, 3 = Somewhat, 4 = Quite a bit, and 5 = Very much. The total raw score is the sum of the responses to each question and is converted to a T-score. The T-score re-scales the total raw score to a standardized score with a mean of 50 and a standard deviation of 10. T-Scores range from 29.4 to 83.2, with higher scores indicating more fatigue. Negative changes from baseline indicate improvement.
| score on a scale | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD |
|---|---|---|
| Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Cancer Fatigue Short Form (SF) 7a Score (Part 2) | -1.5 ± 0.35 | -1.3 ± 0.34 |
MRD conversion rate was defined as the percentage of participants who convert to MRD \< 10\^-3 after initiation of treatment. The population for MRD analysis included participants whose bone marrow was MRD positive (\>=10\^-3, as determined by central flow cytometry) at baseline prior to randomization.
| percentage of participants | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD |
|---|---|---|
| Percentage of Participants With Measurable Residual Disease (MRD) Conversion in Participants With MRD >= 10^-3 at Baseline (Part 2) | 39.7 (30.69 to 49.16) | 40.8 (31.95 to 50.18) |
Time to deterioration was defined as number of days from randomization to either deterioration of \>= 5 points based on the EORTC QLQ-C30 version 3 or death due to any cause. The GHS/QoL scale includes 2 questions in which participants were asked to rate their overall health and overall quality of life during the past week on a scale from 1 (very poor) to 7 (excellent). The 2 scores were averaged and transformed to a scale from 0 to 100, where a high score represents a high QoL.
| months | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD |
|---|---|---|
| Time to Deterioration in Global Health Status (GHS)/Quality of Life (QoL) in Adult Participants (Part 2) | 1.1 (1.08 to 1.84) | 1.6 (1.05 to 1.97) |
The EQ-5D-5L is a generic preference instrument that has been validated in numerous populations and has 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, each of which are rated on five levels of severity (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, 5: extreme problems) with higher scores representing higher symptom burden. A negative change from baseline indicates improvement in health status.
| score on a scale | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD |
|---|---|---|
| mobility | -0.00 ± 0.05 | -0.06 ± 0.05 |
| self-care | 0.01 ± 0.04 | 0.02 ± 0.04 |
| usual activities | -0.09 ± 0.06 | -0.17 ± 0.06 |
| pain/discomfort | 0.09 ± 0.06 | 0.02 ± 0.06 |
| anxiety/depression | 0.10 ± 0.06 | 0.03 ± 0.05 |
Collected over All-cause mortality and adverse event tables include events reported from the start of safety data collection to the end of the study. The median time on follow-up was 53.2, 60.2, 27.4, and 27.9 months for arms Part 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD, Part 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QD, Part 2: Best Supportive Care, and Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD, respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD | 12/30 (40%) | 9/30 (30%) | 30/30 (100%) |
| Part 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QD | 3/5 (60%) | 2/5 (40%) | 5/5 (100%) |
| Part 2: Best Supportive Care | 46/216 (21.3%) | 66/216 (30.6%) | 179/216 (82.9%) |
| Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD | 56/214 (26.2%) | 97/214 (45.3%) | 200/214 (93.5%) |
| Event | Part 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD | Part 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QD | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD |
|---|---|---|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 0/30 | 1/5 | 0/216 | 1/214 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 0/30 | 1/5 | 0/216 | 1/214 |
| GRAFT VERSUS HOST DISEASEImmune system disorders | 0/30 | 1/5 | 1/216 | 0/214 |
| CYSTITISInfections and infestations | 0/30 | 1/5 | 0/216 | 0/214 |
| PNEUMONIAInfections and infestations | 0/30 | 1/5 | 12/216 | 23/214 |
| PLATELET COUNT DECREASEDInvestigations | 0/30 | 1/5 | 0/216 | 2/214 |
| CONFUSIONAL STATEPsychiatric disorders | 0/30 | 1/5 | 0/216 | 0/214 |
| HAEMATURIARenal and urinary disorders | 0/30 | 1/5 | 0/216 | 0/214 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 0/30 | 1/5 | 0/216 | 1/214 |
| DIARRHOEAGastrointestinal disorders | 2/30 | 0/5 | 2/216 | 3/214 |
| Event | Part 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD | Part 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QD | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD |
|---|---|---|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 15/30 | 2/5 | 23/216 | 82/214 |
| NAUSEAGastrointestinal disorders | 14/30 | 2/5 | 28/216 | 71/214 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 6/30 | 2/5 | 39/216 | 43/214 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 11/30 | 0/5 | 18/216 | 61/214 |
| NEUTROPHIL COUNT DECREASEDInvestigations | 6/30 | 0/5 | 25/216 | 72/214 |
| PLATELET COUNT DECREASEDInvestigations | 6/30 | 1/5 | 23/216 | 72/214 |
| DIARRHOEAGastrointestinal disorders | 9/30 | 1/5 | 37/216 | 41/214 |
| ANAEMIABlood and lymphatic system disorders | 8/30 | 1/5 | 33/216 | 56/214 |
| VOMITINGGastrointestinal disorders | 8/30 | 1/5 | 16/216 | 52/214 |
| FATIGUEGeneral disorders | 8/30 | 0/5 | 16/216 | 43/214 |
| Age, Customized(Participants) | Part 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD | Part 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QD | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD | Total |
|---|---|---|---|---|---|
| < 18 | 0 | 0 | 3 | 2 | 5 |
| >= 18 to < 65 | 18 | 5 | 162 | 171 | 356 |
| >= 65 to < 75 | 11 | 0 | 47 | 39 | 97 |
| >= 75 | 1 | 0 | 4 | 2 | 7 |
| Sex: Female, Male(Participants) | Part 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD | Part 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QD | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD | Total |
|---|---|---|---|---|---|
| Female | 11 | 3 | 90 | 79 | 183 |
| Male | 19 | 2 | 126 | 135 | 282 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD | Part 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QD | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 13 | 12 | 26 |
| Not Hispanic or Latino | 29 | 5 | 203 | 202 | 439 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD | Part 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QD | Part 2: Best Supportive Care | Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 5 | 1 | 85 | 81 | 172 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 2 | 4 | 6 |
| White | 24 | 4 | 127 | 127 | 282 |
| More than one race | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 0 | 0 | 2 | 3 |
Showing the first 100 of 165 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Feb 2020 to primary completion in Sep 2025, 66 months.
Results were first posted in Jun 2026, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Venetoclax · Azacitidine